These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 17972821)

  • 1. [Blockade of 5-HT2 receptors as a mechanism of antihypertensive action of ketanserin].
    Prostran M
    Srp Arh Celok Lek; 1994; 122(3-4):99-102. PubMed ID: 17972821
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ketanserin-induced baroreflex enhancement in spontaneously hypertensive rats depends on central 5-HT(2A) receptors.
    Shen FM; Wang J; Ni CR; Yu JG; Wang WZ; Su DF
    Clin Exp Pharmacol Physiol; 2007 Aug; 34(8):702-7. PubMed ID: 17600544
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Serotonergic antagonist].
    Deguchi F; Saito T; Inagaki Y
    Nihon Rinsho; 1992 Apr; 50 Suppl():770-6. PubMed ID: 1635266
    [No Abstract]   [Full Text] [Related]  

  • 4. Ketanserin in hypertension. Early clinical evaluation and dose finding study of a new 5-HT2 receptor antagonist.
    Andrén L; Svensson A; Dahlöf B; Eggertsen R; Hansson L
    Acta Med Scand; 1983; 214(2):125-30. PubMed ID: 6353879
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of ketanserin in the treatment of the essential arterial hypertension associated with ischemic heart disease.
    Podoleanu D; Cotoi S
    Rom J Intern Med; 1996; 34(1-2):49-54. PubMed ID: 8908630
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [A new antihypertensive: ketanserin].
    Salvini P
    Riv Eur Sci Med Farmacol; 1989 Feb; 11(1):77-84. PubMed ID: 2678304
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ketanserin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in hypertension and peripheral vascular disease.
    Brogden RN; Sorkin EM
    Drugs; 1990 Dec; 40(6):903-49. PubMed ID: 2079001
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Experience with ketanserin and ritanserin in hypertensive patients.
    Hedner T; Persson B
    J Cardiovasc Pharmacol; 1988; 11 Suppl 1():S44-8. PubMed ID: 2459514
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Age-related effects of 5-HT2 antagonists.
    Doyle AE
    J Cardiovasc Pharmacol; 1991; 17 Suppl 5():S29-34. PubMed ID: 1717770
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antihypertensive properties of ketanserin (R 41 468).
    Vanhoutte PM; Van Nueten JM; Symoens J; Janssen PA
    Fed Proc; 1983 Feb; 42(2):182-5. PubMed ID: 6295821
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serotonergic type-2 (5-HT2) antagonists: a novel class of cardiovascular drugs.
    Robertson JI
    J Cardiovasc Pharmacol; 1991; 17 Suppl 5():S48-53. PubMed ID: 1717773
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of a new serotonin antagonist, ketanserin, in experimental and clinical hypertension.
    Hedner T; Persson B
    Am J Hypertens; 1988 Jul; 1(3 Pt 3):317S-323S. PubMed ID: 3046635
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Evaluation of acute and chronic effects of ketanserin in the treatment of hypertension and hypothesis on a new mechanism of action].
    Sechi LA
    Ann Ital Med Int; 1990; 5(4 Pt 2):433-50. PubMed ID: 2102130
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of maternal ketanserin treatment on foetal 5-HT receptor function in umbilical cord artery of pre-eclamptic patients.
    Hanff LM; Gupta S; MaassenVanDenBrink A; Steegers EA; Saxena PR; Vulto AG; Visser W
    Neonatology; 2007; 92(4):240-7. PubMed ID: 17556842
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical aspects during therapy with the serotonin antagonist ketanserin.
    Distler A
    Clin Physiol Biochem; 1990; 8 Suppl 3():64-80. PubMed ID: 1983424
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Age and 5HT 2-receptor blockade with ketanserin in essential hypertension.
    Bühler FR; Amstein R
    Rev Port Cardiol; 1989 Sep; 8(9):621-4. PubMed ID: 2698721
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Mechanism of action and use of antagonists of serotonin receptors S2, especially ketanserin, in the treatment of various diseases of the cardiovascular system].
    Wiecek A; Grzeszczak W
    Pol Tyg Lek; 1987 Mar; 42(10):304-8. PubMed ID: 3299308
    [No Abstract]   [Full Text] [Related]  

  • 18. Role of alpha-adrenergic blockade in the cardiovascular actions of ketanserin: studies in patients with essential hypertension, autonomic insufficiency, and Raynaud's phenomenon.
    Brouwer RM; Wenting GJ; Man in't Veld AJ; Schalekamp MA
    J Cardiovasc Pharmacol; 1987; 10 Suppl 3():S26-31. PubMed ID: 2446064
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The rationale for ketanserin therapy in hypertension.
    Hansson L; Hedner T
    J Cardiovasc Pharmacol; 1987; 10 Suppl 3():S39-44. PubMed ID: 2446068
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ketanserin (S2-receptor blocking agents), hypertension and chronic alcoholism.
    De Lorenzo A; Ceccanti M; Romeo M; Pisculli M; Di Giovanni MG; Lais A; Assogna G; Valgiusti FC
    Int J Clin Pharmacol Res; 1986; 6(1):77-9. PubMed ID: 2937747
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.